Abstract
Objectives: Given that the effect of omalizumab in atopic dermatitis (AD) is controversial, the aim of this study was to evaluate its efficacy. Methods: We retrospectively reviewed the medical records of twelve patients with severe refractory AD who had received either dose of 150 or 300mg omalizumab therapy between 2012 and 2015. Scoring atopic dermatitis (SCORAD) and dermatology life quality index (DLQI) scores were evaluated before and 3 months after omalizumab therapy. Results: All our 12 patients had severe refractory AD (SCORAD ＞ 40). The SCORAD and DLQI scores after 3 months of omalizumab therapy were from 64.9 ± 12.3 to 38.9 ± 8.4 (p ＜ 0.001), and 21.9 ± 3.3 to 13.0 ± 4.5 (p ＜ 0.001) respectively. There was no statistically significant difference in the values of SCORAD and DLQI between patients treated with 150mg and 300mg omalizumab (SCORAD, p = 0.485; DLQI, p = 0.818). The reduction of SCORAD by omalizumab was significantly greater in AD patients with a very high SCORAD score (SCORAD ＞ 60) compared to those with a low SCORAD score (32.8 ± 8.1% vs. 16.5 ± 10.4%, p = 0.010). In addition, the degree of reduction of SCORAD or DLQI did not achieve significant difference between patients with or without received systemic glucocorticoid (SCORAD, p = 0.310; DLQI, p = 0.937). Conclusion: Omalizumab may be an effective therapy for AD patients, but further studies are needed to substantiate our findings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
